Optic Atrophy Market

Market Overview:

The 7 major optic atrophy markets reached a value of US$ 5.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8.4 Billion by 2034, exhibiting a growth rate (CAGR) of 3.76% during 2024-2034.

The optic atrophy market has been comprehensively analyzed in IMARC's new report titled "Optic Atrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Optic atrophy, a medical condition characterized by the degeneration of the optic nerve, leads to a progressive loss of vision and can result from various underlying causes. The optic nerve, essential for transmitting visual information from the eyes to the brain, undergoes damage and subsequent shrinkage in optic atrophy. This condition often manifests as a gradual decline in visual acuity, reduced color perception, and a constricted visual field. Patients may experience difficulties with tasks requiring sharp vision, such as reading, recognizing faces, and navigating their surroundings. The diagnosis of this ailment involves a comprehensive medical evaluation. Ophthalmologists typically perform a detailed eye examination, including visual acuity tests, color vision assessments, and visual field testing. Fundoscopic analysis of the optic nerve head is also recommended to reveal characteristic changes, such as pallor and thinning of the nerve fibers. Several imaging techniques, like optical coherence tomography (OCT), are utilized to obtain in-depth insights into the structure of the optic nerve.

The escalating cases of genetic abnormalities that can cause mutations in the GNAQ gene, resulting in the aberrant growth of blood vessels in vital regions like the optic nerve, are primarily driving the optic atrophy market. In addition to this, the inflating utilization of efficacious therapeutic interventions, including neuroprotective agents, mitochondrial enhancers, stem cell therapies, etc., since they are aimed at managing the condition and preventing further nerve damage, is also creating a positive outlook for the market. Moreover, the widespread adoption of visual rehabilitation techniques and low vision aids, which help in enhancing visual function, field, and acuity, is propelling the market growth. These interventions contribute to fortifying the optic nerve pathways, thereby improving visual processing and bolstering overall visual capabilities. Apart from this, the rising usage of innovative surgical procedures, such as optic nerve decompression and nerve fiber layer implants, to alleviate pressure on the optic nerve and potentially restore or maintain optimal visual function is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy that entails the introduction of functional genetic material to rectify or replace mutated genes responsible for the condition is expected to drive the optic atrophy market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the optic atrophy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for optic atrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the optic atrophy market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the optic atrophy market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the optic atrophy market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current optic atrophy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the optic atrophy market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the optic atrophy market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the optic atrophy market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of optic atrophy across the seven major markets?
• What is the number of prevalent cases (2018-2034) of optic atrophy by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of optic atrophy by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with optic atrophy across the seven major markets?
• What is the size of the optic atrophy patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of optic atrophy?
• What will be the growth rate of patients across the seven major markets?
   

Optic Atrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for optic atrophy drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the optic atrophy market?
• What are the key regulatory events related to the optic atrophy market?
• What is the structure of clinical trial landscape by status related to the optic atrophy market?
• What is the structure of clinical trial landscape by phase related to the optic atrophy market?
• What is the structure of clinical trial landscape by route of administration related to the optic atrophy market?